Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April
Ocular Therapeutix, Inc. announced plans to present new data from their Phase 3 clinical trial of AXPAXLI (OTX-TKI) for wet age-related macular degeneration at upcoming scientific conferences in April 2026. The presentations aim to highlight the drug's efficacy and support its therapeutic potential, with sessions scheduled at the Vit-Buckle Society…